Iovance Biotherapeutics, Inc.
IOVA
$6.98
$0.467.06%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -289.52M | -353.86M | -390.98M | -397.63M | -389.92M |
| Total Depreciation and Amortization | 45.14M | 46.96M | 47.48M | 52.00M | 50.46M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.74M | 55.92M | 65.51M | 83.08M | 100.41M |
| Change in Net Operating Assets | -64.54M | -19.82M | -24.43M | -60.59M | -64.36M |
| Cash from Operations | -264.18M | -270.79M | -302.41M | -323.14M | -303.41M |
| Capital Expenditure | -32.21M | -34.23M | -33.84M | -28.68M | -20.13M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 0.00 | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -12.66M | 77.26M | 81.33M | 99.08M | 24.71M |
| Cash from Investing | -44.87M | 43.02M | 47.50M | 70.40M | 4.59M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 294.11M | 257.39M | 307.83M | 254.40M | 214.11M |
| Repurchase of Common Stock | -6.26M | -5.59M | -7.06M | -7.49M | -13.31M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 287.85M | 251.79M | 300.77M | 246.91M | 200.81M |
| Foreign Exchange rate Adjustments | -440.00K | 423.00K | 1.14M | -611.00K | 1.32M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.64M | 24.45M | 47.01M | -6.44M | -96.70M |